We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

121 hedge funds and large institutions have $112M invested in Ventyx Biosciences in 2023 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 31 increasing their positions, 33 reducing their positions, and 61 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 33

12% less funds holding

Funds holding: 138121 (-17)

16.19% less ownership

Funds ownership: 92.69%76.5% (-16%)

26% less first-time investments, than exits

New positions opened: 45 | Existing positions closed: 61

67% less funds holding in top 10

Funds holding in top 10: 31 (-2)

86% less call options, than puts

Call options by funds: $426K | Put options by funds: $2.95M

94% less capital invested

Capital invested by funds: $1.9B → $112M (-$1.78B)

Holders
121
Holders Change
-17
Holders Change %
-12.32%
% of All Funds
1.76%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
45
Increased
31
Reduced
33
Closed
61
Calls
$426K
Puts
$2.95M
Net Calls
-$2.52M
Net Calls Change
-$1.6M
Name Holding Trade Value Shares
Change
Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$10.5M +$12.6M +1,326,472 +45%
Morgan Stanley
2
Morgan Stanley
New York
$9.46M +$33.7M +3,545,945 +1,248%
BlackRock
3
BlackRock
New York
$9.42M +$1.77M +186,311 +5%
Vanguard Group
4
Vanguard Group
Pennsylvania
$9.24M +$10.2M +1,079,254 +41%
Capital International Investors
5
Capital International Investors
California
$5.81M -$3.55M -373,703 -14%
LGM
6
Logos Global Management
California
$4.94M +$16.9M +1,775,000 +789%
TCM
7
Tang Capital Management
California
$4.94M +$19M +2,000,000 New
Millennium Management
8
Millennium Management
New York
$4.78M +$17.8M +1,875,786 +3,192%
Goldman Sachs
9
Goldman Sachs
New York
$3.37M -$2.4M -252,757 -16%
OM
10
Opaleye Management
Massachusetts
$2.82M +$10.8M +1,140,000 New
Two Sigma Investments
11
Two Sigma Investments
New York
$2.79M +$10.3M +1,083,138 +2,386%
Two Sigma Advisers
12
Two Sigma Advisers
New York
$2.74M +$10.5M +1,109,100 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$2.53M +$473K +49,809 +5%
State Street
14
State Street
Massachusetts
$2.45M -$1.01M -106,096 -10%
Qube Research & Technologies (QRT)
15
Qube Research & Technologies (QRT)
United Kingdom
$2.33M +$8.94M +941,556 New
TCM
16
TCG Crossover Management
California
$2.01M
BCM
17
Bridgeway Capital Management
Texas
$1.76M +$6.75M +710,800 New
QUSVM
18
Qiming U.S. Ventures Management
Washington
$1.7M
Adage Capital Partners
19
Adage Capital Partners
Massachusetts
$1.48M -$3.68M -387,970 -39%
Marshall Wace
20
Marshall Wace
United Kingdom
$1.29M +$1.79M +188,121 +56%
D.E. Shaw & Co
21
D.E. Shaw & Co
New York
$1.27M +$4.89M +514,619 New
IHAM
22
Integral Health Asset Management
New York
$1.24M +$665K +70,000 +16%
American Century Companies
23
American Century Companies
Missouri
$1.18M +$2.17M +228,640 +92%
GCM
24
Graham Capital Management
Connecticut
$1.14M +$4.4M +463,117 New
Jane Street
25
Jane Street
New York
$1.14M +$4.24M +446,782 +2,907%

VTYX Hedge Fund Activity: Q4 2023 in Review

121 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q4 2023, worth a combined $112M — down 94% from $1.9B a quarter earlier.

Sellers outnumbered buyers: 61 funds closed out of VTYX and 45 opened new positions — a net loss of 16 holders — while 33 trimmed existing stakes and 31 added.

The largest buyer was Morgan Stanley, adding an estimated $33.7M. The largest seller was Fidelity Investments, cutting an estimated $81.8M.

  • 121 institutional investors held Ventyx Biosciences (VTYX) as of Q4 2023, down from 138 in Q3 2023.
  • Funds reported $112M of Ventyx Biosciences stock for Q4 2023, down 94% quarter-over-quarter.
  • 45 funds opened new Ventyx Biosciences positions in Q4 2023 and 61 closed out, a net change of -16 holders.
  • The largest Ventyx Biosciences buyer in Q4 2023 was Morgan Stanley, an estimated $33.7M added.
  • The largest Ventyx Biosciences seller in Q4 2023 was Fidelity Investments, an estimated $81.8M sold.

Based on aggregated 13F filings for Q4 2023.